Thursday April 18, 2019

Medical online startups attracting foreign patients to India

0
//
startups
Image source: keweenawhealth.com

New Delhi: India, ‘the pharmacy of the developing world’, sees foreign patients flocking to the country due to its specialised and cost-effective medical care. This has resulted in the mushrooming of online startups that help foreign nationals find the best treatment in the country.

One such medical tourism start-up, PlanMyMedicalTrip.com, which was started nine years back, is now serving as a one-stop solution provider for foreign medical tourists.

“We have patients coming in from all over the world. However, Africa, GCC (Gulf Cooperation Council) and CIS (Commonwealth of Independent States) regions contribute towards the sector by as much as 30 percent of the total inflow,” said Anurav Rane, CEO, PlanMyMedicalTrip.com.

“There are a lot of different medical and surgical options for medical tourists coming to India. Primarily, medical tourists get elective procedures done such as cosmetic surgery, hip and knee replacements, dental procedures and infertility treatments,” he told reporters.

According to a white paper by the Confederation of Indian Industry (CII) and Grant Thornton, the Indian medical tourism market is set to touch $8 billion by 2020, up from the current $3 billion.

Saed Saber from Egypt recently came to India for knee replacement. “I wanted to get my knee replacement done but was confused as to how I should go about it. Since options in my country are limited with a high price tag for treatment, I started exploring for options, that is when I came to know about PlanMyMedicalTrip.com,” he said.

Saber visited PlanMyMedicalTrip.com to get his queries answered. “I got to know several options for hospitals across India and also got all the necessary procedures sorted for me in no time,” he told reporters.

IndiaHealthCareTourism.com, inaugurated recently by Prime Minister Narendra Modi, is an initiative by the government to boost healthcare tourism. It is a web portal that helps and guides the patients who are looking for treatment options in India. It lists 93 topmost medical centres, 30 Ayurveda and wellness centres and one special category centre.

Another online venture, Medi Connect India, deals with the latest technologies like IVF (infertility), robotics surgeries, stem cell therapies, etc.

“The main reason behind India becoming a hub for medical tourism for foreigners is cost-effectiveness. Here in metro cities, you would get world-class treatment under the best doctors in a much cheaper way than what they would end up paying in their respective countries,” Shalini, assistant team lead, Medi Connect India, told reporters.

“In countries like Africa, a lot of modern treatments and good doctors are not available and hence they find India a good destination for medical reasons. Here, the best treatments are available with no waiting time in the company of highly-qualified doctors,” she added.

Medi Connect India has won the “National Tourism Award” for two consecutive years for excellence in medical tourism.

To serve foreign nationals better, most of the top-rated hospitals in India have also hired language translators to make patients, especially from Balkan and African countries, feel comfortable and help facilitate their treatment.

According to the CII-Grant Thornton white paper, Chennai, Mumbai, Andhra Pradesh and Delhi-NCR are the most favoured medical tourism destinations for foreigners who avail treatments in India.

Cost is a major driver for nearly 80 percent of medical tourists across the globe, it added.

The cost factor and availability of accredited facilities have led to the emergence of several global medical tourism corridors like Singapore, Thailand, India, Malaysia, Taiwan, Mexico and Costa Rica- and India appears to have taken a lead. (Vivek Singh Chauhan, IANS)

Next Story

Blood Cancer: Stem Cell Protein Play An Important Role in Cure

The stem cell protein Asrij is misexpressed in several human hematological malignancies and implicated in the p53 pathway and DNA damage response, the team said.

0
cancer
According to the study, published in the journal Blood, inactivation of the tumour suppressor p53 is essential for unrestrained growth of cancers. But only 11 per cent of hematological malignancies have mutant p53. VOA

Researchers have identified a stem cell protein that may help in finding cure for blood cancer.

The study, done on mice, suggests a stem cell protein called Asrij is a novel regulator of wild type tumour suppressor p53 stability in hematopoietic stem cells (HSCs).

cancer
According to the study, published in the journal Blood, inactivation of the tumour suppressor p53 is essential for unrestrained growth of cancers. But only 11 per cent of hematological malignancies have mutant p53. Pixabay

It could help design targeted therapies for myeloproliferative disease, a group of slow-growing blood cancers, according to researchers, including Maneesha S. Inamdar from the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru.

“We provide a new mouse model resembling myeloproliferative disease and identify a post-translational regulator of wild type p53 essential for maintaining HSC quiescence that could be a potential target for pharmacological intervention,” the team said.

According to the study, published in the journal Blood, inactivation of the tumour suppressor p53 is essential for unrestrained growth of cancers. But only 11 per cent of hematological malignancies have mutant p53.

microscope
The study, done on mice, suggests a stem cell protein called Asrij is a novel regulator of wild type tumour suppressor p53 stability in hematopoietic stem cells (HSCs). Pixabay

Mechanisms that cause wild type p53 dysfunction and promote leukemia are inadequately deciphered, suggests the study.

Also Read: How is Media Effecting Political Situations in India Today?

The stem cell protein Asrij is misexpressed in several human hematological malignancies and implicated in the p53 pathway and DNA damage response, the team said.

For the study, the team generated the first Asrij null (knockout, KO) in mice and showed they are viable and fertile with no gross abnormalities. However, by six months, they exhibited increased peripheral blood cell counts, splenomegaly and an expansion of bone marrow HSCs with higher myeloid output. (IANS)